Introduction
============

Sequential synaptic inputs often cause dendritic spikes. Fast-acting membrane depolarization in the dendritic tree is converted into axo-somatic action potentials (APs) that do not only propagate down the axon but also back into the dendritic tree ([@B42]; [@B11]). With distance from the soma, the amplitude of back-propagation action potentials (bAPs) is gradually attenuated by the inhibitory action of A-type transient potassium channels, I~A~ for short ([@B53]; [@B40]). It is because the density of these channels gradually increases from the soma to distal dendrites. In addition to the role of I~A~ on feedback propagation, the channels play a critical role in feedforward, pre-to-post-synaptic transmission and integration by suppressing dendritic spikes ([@B20]; [@B64]; [@B59]; [@B63]; [@B121]). Therefore, a dysfunction of I~A~ channels can lead to loss of control over neuronal excitability, the hallmark of several diseases in the brain. In this review, we discuss (1) the distribution (mostly in human) and function (in animals and human) of I~A~ channels in the brain, (2) the common down-regulation of I~A~ channels in several brain diseases and (3) a potential I~A~ channel-based therapeutic target.

Subtypes of I~A~ Channels
=========================

The potassium channels form a large and diverse family of ion channels that are involved in establishing the resting membrane potential, determining the action potential waveform, regulating neurotransmitter release, and modulating rhythmic firing patterns ([@B75]; [@B58]). There are four major classes of potassium channels in the brain: Calcium-activated, inwardly rectifying, leak, and voltage-gated potassium channel. Particularly, I~A~ channels, one type of voltage-gated potassium channels, are characterized by closed, opened, and inactivated channel states depending on the membrane voltage. I~A~ channels form a large macromolecular complex comprising four ion-conducting alpha-subunits and beta-subunits (either being cytoplasmic or transmembrane) with auxiliary regulatory and supporting proteins ([@B72]; [@B44]). This voltage-gated potassium channels usually have a homotetrameric structure (with all alpha-subunits being identical), but some of them are heterotetrameric (with two or more non-identical alpha-subunits) ([@B95]; [@B44]). The alpha-subunits (Kv1.4, Kv3.3, Kv3.4, Kv4.1, Kv4.2, and Kv4.3) that are divided into discrete families on the basis of sequence similarity form an ion pore and infrastructure of the channel. The alpha-subunits determine the fast kinetic property of I~A~ channels, rapidly activating and inactivating ([@B27]; [@B28]). The alpha-subunits are major components on which pharmacological agents target. Most generally used 4-aminopyridine (4-AP) not only blocks the subtypes of I~A~ channels such as Kv1.4 and Kv4.x, but also other subtypes of voltage-gated potassium channels ([@B46]). Alternatively, biotoxins isolated from venoms of the tarantula spider (PaTx1 and 2, HmTx1, HpTx1 and 2), sea anemone (BDS I and II) and scorpion (alpha-KTx15 subfamily) have relatively higher selectivity on the specific subtypes of I~A~ channels ([@B91]; [@B33]; [@B39]; [@B123]; [@B86]). Plus, some components (Diclofenac and BmP02) have been identified to activate I~A~ channels ([@B74]; [@B111],[@B112]).

Meanwhile, the beta-subunits and other auxiliary subunits of I~A~ channels are known for modulating the biophysical properties and functions of I~A~ channels ([@B52]; [@B27]; [@B2]; [@B3]; [@B104]; [@B9]; [@B124]; [@B84]; [@B41]). The alpha-subunit in the Kv1 complex interacts with the amino-terminal tetramerization domain of Kv beta-proteins which regulates the gating of the channels ([@B113]). The Kv3 complex contains potassium voltage-gated channel subfamily E regulatory subunit 3 (KCNE3) which is known to carry a fast inactivating current ([@B113]). The Kv4 complex has been associated with various ancillary subunits or scaffolding proteins including Kv beta-subunits ([@B1]), dipeptidyl peptidase (DPP) family members (DPP6 and DPP10) ([@B84]; [@B56]) and K^+^ channel-interacting proteins (KChIP1, KChIP2, KChIP3, and KChIP4) ([@B2]; [@B81]). In particular, the KChIPs are required for function and formation of the Kv4 complex ([@B80]) while DPPs and beta-subunits contribute to the alteration of Kv4 currents ([@B114]; [@B56]).

The activity and expression of I~A~ channels can be modulated by certain post-translational modifications of phosphorylation and palmitoylation ([@B113]) with various protein kinases such as Ca^2+^/calmodulin-dependent protein kinase II (CaMKII), cAMP-dependent protein kinase (PKA), protein kinase C (PKC), and mitogen-activated protein kinase (MAPK) ([@B57]). CaMKII phosphorylation of Kv1.4 is reported to regulate the inactivation gate of I~A~ channels arising from Kv1.4 ([@B87]; [@B105]). Similarly, CaMKII phosphorylated Kv4.2 upregulates both the expression level of Kv4.2 proteins and the peak current of Kv4.2 ([@B87]; [@B105]). Meanwhile, either PKA or PKC activation decreases the opening of I~A~ channels encoded mostly by Kv4.2; accordingly, their activation increases the amplitude of bAPs in distal dendrites ([@B52]). In other studies, PKC reduces inactivation of I~A~ channels encoded by Kv3.3 and Kv3.4 ([@B29]). Thus, the complex structure of I~A~ channels likely determines their class and functions.

In this review, an attention is also made to (1) the microscopic expression pattern and (2) kinetics of Kv1.4 (*kcna4*), Kv3.3 (*kcnc3*), Kv3.4 (*kcnc4*), Kv4.1 (*kcnd1*), Kv4.2 (*kcnd2*), and Kv4.3 (*kcnd3*) which are the most common alpha-subunits of I~A~ channels ([@B27]; [@B28]). Firstly, as for the I~A~ expression pattern in a neuron, pioneering works for characteristic I~A~ channels on the dendrites show that 4-AP (a non-selective I~A~ blocker)-sensitive I~A~ channels are distributed along the apical dendritic truck and tuft of L5B pyramidal neurons in mice ([@B10]; [@B66]; [@B48]). Specifically, Kv1.4 and Kv3.4 channels are largely localized in axons and dendrites ([@B106]; [@B92]) while Kv3.3 is mostly located in distal dendrites ([@B106]; [@B65]; [@B24]). Also, Kv4 family such as Kv4.1, Kv4.2, Kv4.3 is primarily found in somatodendritic membrane although Kv4.2 channels are highly concentrated in dendrites ([@B27]; [@B89]; [@B96]; [@B65]; [@B61]). Secondly, Kv3 subfamily (encoding Kv3.1, Kv3.2, Kv3.3, and Kv3.4) has distinct functional properties; they activate at high thresholds (-10 mV) with rapid kinetics ([@B89]; [@B126]). In fact, homomeric Kv3.1 and Kv3.2 channels have slower inactivation kinetics than heteromultimeric Kv3.1/Kv3.4 and Kv3.2/Kv3.4 channels carrying a fast inactivating component ([@B89]). Also, Kv4 channels show the fast recovery from inactivation state, a hallmark of somatodendritic I~A~ channels. In general, I~A~ channels respond transiently to stimuli, exhibiting a rapidly activating and inactivating kinetic. They affect the excitability and firing properties of neurons via regulatory actions of their pore-forming alpha-subunits, each of which has slightly different sensitivity to voltage changes ([@B76]; [@B22]).

Close Association of I~A~ With Several Brain Diseases
=====================================================

Subtypes of I~A~ channels are differentially distributed in the brain. The macroscopic expression pattern of I~A~ channels is now investigated with human brain where clinical value can be highlighted. Kv1.4 is predominantly expressed in prefrontal cortex, cerebellum peduncles, pituitary and pineal gland in a ranking order; kv3.3 in prefrontal cortex, pineal gland, pituitary and cerebellum peduncles; kv3.4 in cerebellum peduncles, pituitary, prefrontal cortex and pineal gland; kv4.1 in pineal gland, prefrontal cortex, pituitary and cerebellum peduncles; kv4.2 in cerebellum peduncles, cerebellum, prefrontal cortex and hypothalamus; kv4.3 in subthalamic nucleus, pineal gland, cerebellum peduncles and prefrontal cortex ([Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). Furthermore, there are significant functional consequences of I~A~ on brain disorders ([Table 2](#T2){ref-type="table"}). Interestingly, the mRNA expression of I~A~ channels is largely downregulated in the condition of brain dysfunction ([Table 3](#T3){ref-type="table"}). In the following sections, we discuss the tight involvement of I~A~ channels in brain diseases, such as Alzheimer's disease, epilepsy, fragile X syndrome (FXS), Parkinson's disease, chronic pain, tinnitus and ataxia.

![mRNA expression levels of panel **(A)** *kcna4* (Kv1.4), *kcnc3* (Kv3.3), and *kcnc4* (Kv3.4), panel **(B)** *kcnd1* (Kv4.1), *kcnd2* (Kv4.2), *and kcnd3* (Kv4.3). The microarray data have the mean value of each probe-set data obtained from BIOGPS (<http://www.biogps.org>), showing the tissue-specific pattern of mRNA expression according to GeneAtlas U133A, gcrma ([@B97]). Note that expression of Kv1.4 is elevated in prefrontal cortex, cerebellum peduncles, pituitary and pineal gland; Kv3.3 in prefrontal cortex, pineal gland, pituitary, cerebellum peduncles; Kv3.4 in cerebellum peduncles, pituitary, prefrontal cortex and pineal gland; Kv4.1 in pineal gland, prefrontal cortex, pituitary and cerebellum peduncles; Kv4.2 in cerebellum peduncles, cerebellum, and prefrontal cortex and hypothalamus; Kv4.3 in subthalamic nucleus, pineal gland, cerebellum peduncles, pituitary and prefrontal cortex (when only top 25% of expression levels is considered).](fncel-13-00265-g001){#F1}

###### 

mRNA expression levels of each I~A~ channel subunit on the human brain.

                         mRNA Expression Level                                
  ---------------------- ----------------------- ------ ------ ------ ------- -------
  Olfactory bulb         6.1                     3.2    3.3    3.7    5.65    4.9
  Globus pallidus        5.95                    2.95   3.1    3.4    5.85    5.15
  Occipital lobe         7.15                    3.7    3.85   4.2    6.55    5.525
  Medulla oblongata      7.05                    3.8    4.9    4.3    6.6     5.875
  Pons                   7.75                    3.9    4.8    4.45   7.35    6.75
  Subthalamic nucleus    7.45                    3.65   3.9    5.05   7.55    7.9
  Amygdala               8.3                     4.4    4.45   4.95   7.9     6.125
  Caudate nucleus        7.1                     3.7    3.8    4.15   8.3     6.1
  Parietal lobe          8.4                     4.25   4.6    5      8.4     6.925
  Thalamus               8.05                    4.1    4.35   4.75   8.55    6.6
  Pituitary              9.65                    4.75   5.5    5.45   8.65    7.325
  Temporal lobe          7.2                     3.75   3.85   4.25   8.65    6.675
  Pineal grand           9.88                    5.05   5.11   6.36   8.74    7.465
  Cingulate cortex       8.1                     4.2    4.3    4.8    9.4     6.75
  Hypothalamus           7.95                    4.5    4.45   5.1    10.75   6.5
  Prefrontal cortex      9.2                     5.1    5.2    5.75   13.65   7.325
  Cerebellum             6.4                     3.45   3.4    3.85   21.05   5.15
  Cerebellum peduncles   9                       4.6    5.55   5.35   58.2    7.4
                                                                              

The microarray data have the mean value of each probe-set data obtained from BIOGPS (

http://www.biogps.org

), showing the tissue-specific pattern of mRNA expression according to GeneAtlas U133A, gcrma (

Su et al., 2004

): KCNA4 (

http://ds.biogps.org/dataset=GSE1133&gene=3739

); KCNC3 (

http://ds.biogps.org/dataset=GSE1133&gene=3748

); KCNC4 (

http://ds.biogps.org/?dataset=GSE1133&gene=3749

); KCND1 (

http://ds.biogps.org/?dataset=GSE1133&gene=3750

); KCND2 (

http://ds.biogps.org/?dataset=GSE1133&gene=3751

); KCND3 (

http://ds.biogps.org/?dataset=GSE1133&gene=3752

).

###### 

The close association of I~A~ channel activity and expression in brain diseases.

  Brain Disease   Subject                                                 Regions                                  Central Findings                                                                                                                                                                                           References
  --------------- ------------------------------------------------------- ---------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  Alzheimer's     mouse CA1                                               Hippocampus (CA1)                        A~β~ reduces I~A~ conductance; reduced I~A~ current causes increased Ca2+ influx and excitotoxicity.                                                                                                       [@B82]
                  SD rats (7--14 weeks)                                                                            A~β~ causes loss of Ca2+ regulation by inhibiting I~A~ channels in hippocampal CA1 pyramidal neurons, leading to functional and/or structural synaptic deficits in hippocampus.                            [@B25]
                  mouse (3 months)                                                                                 A~β~-induced dendritic hyperexcitability is associated with the depletion of Kv4.2 and abnormalities in both EEG (electroencephalography) and behavior.                                                    [@B47]
  Epilepsy        Wistar rats (adult male)                                Hippocampus                              The expression of I~A~ channel subunit Kv4.2 is selectively reduced in ischemic rats with spontaneous behavioral seizures and increased seizure susceptibility.                                            [@B71]
                  mouse (12 and 30 weeks)                                                                          Kv 4.2 deficiency contributes to aberrant network excitability and increased seizure susceptibility.                                                                                                       [@B8]
                  SD rat                                                  Hippocampus (CA1)                        Lack of I~A~ channels contributes to increased excitability and lowered seizure thresholds.                                                                                                                [@B23]
                                                                          Hippocampus                              Altered phosphorylation and localization of Kv4.2 in status epilepticus.                                                                                                                                   [@B79]
                  human                                                   Temporal lobe (Amygdala/hippocampus)     Temporal lobe epilepsy patient carries an I~A~ channel gene mutation, namely a Kv4.2 truncation mutation. This mutation causes aberrant neuronal excitability, characteristic of temporal lobe epilepsy.   [@B93]
  Fragile X       *Fmr1* K.O mouse (3 and 8 weeks)                        Hippocampus (CA1 and dentate gyrus)      Loss of FMRP expression causes the dendritic downregulation of Kv4.2 channels, possibly leading to neuronal hyperexcitability.                                                                             [@B45]
                  *Fmr1* K.O mouse (5--7 weeks)                           Hippocampus (CA1)                        Functional Kv4.× channels in the dendrites of CA1 pyramidal neurons are downregulated.                                                                                                                     [@B88]
                  *Fmr1* K.O mouse (Varied age)                                                                    A lack of FMRP decreased Kv4.2 expression in dendrite, but the Kv4.2 was restored with NMDA treatment.                                                                                                     [@B69]
  Tinnitus        hearing loss-induced tinnitus animal model (3 months)   Temporal Lobe (Auditory Cortex)          Downregulation of Kv1.4 gene expression in auditory cortex in a noise-induced animal model of tinnitus.                                                                                                    [@B100]
  Parkinson's     A53T-SNCA mice (7--8 months)                            Brainstem SN/VTA                         A dysfunction of Kv 4.3 channels increases intrinsic firing rates of DA SN neurons in part by increasing their intrinsic pacemaker frequency.                                                              [@B99]
  Chronic Pain    CD-1 mouse, 129SvEv, Kv4.2^-^/^-^ model (4--10 days)    Cultured/Sliced Spinal Cord DH neurons   Kv4.2 knockout in mice up-regulates hypersensitivity to tactile and thermal stimuli.                                                                                                                       [@B55]
                  SD rats, Cystitis model (170--220 g)                    DRG neuron                               Reduction of I~A~ contributes to hyperexcitability of capsaicin-sensitive C-fiber bladder afferent neurons in rats with HCl-induced cystitis.                                                              [@B49]
                  SD rats, diabetic neuropathic model (9 weeks old)                                                Reduction of I~A~ in primary sensory neurons in a rat diabetic neuropathy model.                                                                                                                           [@B21]
                  SD rats, neuropathic pain model (250--300 g)                                                     Protein expression of Kv4.3 in DRG neurons is decreased in a rat neuropathic pain model, leading to mechanical hypersensitivity.                                                                           [@B26]
                  C57BL/6J mouse, neuropathic pain model (20--25 g)                                                Peripheral nerve injury decreases the mRNA level of Kv4.3 expression.                                                                                                                                      [@B102]
  Ataxia          HEK293T cells                                           HEK293T cells                            KCND3 mutations cause SCA19 by impaired protein maturation and/or reduced channel function                                                                                                                 [@B36]
                                                                                                                   Autosomal dominant cerebellar ataxia (SCA type 22) shows heterozygous mutations in the voltage-gated potassium channel Kv4.3-encording KCND3 gene.                                                         [@B70]
                  CHO cells                                               CHO cells                                Kv3.3 gene mutations on chromosome 19q13 cause the neurological disorder SCA type 13.                                                                                                                      [@B126]
                  Filipino for cerebellar Ataxia                          *Xenopus laevis* oocytes                 Mutation associated with SCA type 13 alter KCNC3 function and expression in expression systems of *Xenopus laevis* which were injected by Filipino-cerebellar ataxia cDNA clone.                           [@B109]
                                                                                                                                                                                                                                                                                                                              

Ab, amyloid beta; SD, sprague dowley; FMRP, fragile X mental retardation protein; SN, substantia nigra; VTA, ventral tegmental area; DRG, dorsal root ganglion; DH, dorsal horn.

###### 

Effects of I~A~ channel mRNA expression in brain diseases.

  Brain Diseases                Subject                              Region                        Genetic Basis of I~A~ Channel   *P*-Value Control vs. Brain Diseases   References
  ----------------------------- ------------------------------------ ----------------------------- ------------------------------- -------------------------------------- ------------
  Alzheimer's disease           Human patient                        Temporal lobe                 KCNA4_1                         0.099                                  GSE6834
                                                                                                   KCNA4_2                         0.086                                  
                                                                                                   KCNA4_3                         0.078                                  
                                Human patient                        Cerebellum                    KCNA4_1                         0.070                                  
                                                                                                   KCNC3_1                         0.081                                  
                                                                                                   KCND2_1                         0.072                                  
                                Human patient                        Frontal cortex                KCND2_1                         0.071                                  GSE36980
                                                                     Temporal cortex               KCND2_1                         0.006^\*\*^                            
                                                                                                   KCND3_1                         0.043^\*^                              
                                                                     Hippocampus                   KCNA4_1                         0.081                                  
                                                                                                   KCND2_1                         0.079                                  
                                                                                                   KCND3_1                         0.0002^\*\*^                           
  Parkinson's disease           Human post-mortem                    Putamen (basal ganglia)       KCNA4_1                         0.040^\*^                              GSE20291
                                                                                                   KCNC3_1                         0.038^\*^                              
                                                                                                   KCNC4_1                         0.050                                  
                                                                                                   KCND1_1                         0.068                                  
                                                                                                   KCND2_1                         0.026^\*^                              
                                                                                                   KCND3_1                         0.029^\*^                              
                                                                                                   KCND3_2                         0.034^\*^                              
                                                                                                   KCND3_3                         0.044^\*^                              
                                                                                                   KCND3_4                         0.076                                  
                                                                     Prefrontal area 9             KCND2_1                         0.058                                  GSE20168
                                                                                                   KCND3_1                         0.012^\*^                              
  Epilepsy                      Human patient                        Temporal lobe                 KCNC3_1                         0.0002^\*\*^                           GSE6834
                                                                                                   KCNC3_2                         0.0004^\*\*^                           
                                                                                                   KCNC3_3                         0.004^\*\*^                            
  Epilepsy                      Human patient                        Temporal lobe                 KCNC3_4                         0.048^\*^                              GSE6834
                                                                                                   KCNC4_1                         0.030^\*^                              
                                                                                                   KCNC4_2                         0.059                                  
                                                                                                   KCND2_1                         0.102                                  
                                                                                                   KCND3_1                         0.008^\*\*^                            
                                                                                                   KCND3_2                         0.011^\*^                              
  Epilepsy (Febrile seizures)   Human patient                        Hippocampal CA3               KCNA4_1                         0.001^\*\*^                            GSE28674
                                                                                                   KCNC3_1                         0.002^\*\*^                            
                                                                                                   KCND2_1                         0.024^\*^                              
                                                                                                   KCND2_2                         0.029^\*^                              
  Fragile X syndrome            Mouse (4, 8, 12 weeks)               Cerebellar purkinje cells     KCNA4_1                         0.071                                  GSE57034
                                                                                                   KCND2_1                         0.064                                  
                                                                                                   KCND3_1                         0.040^\*^                              
                                Embryo mouse (17--18 days)           Cortex                        KCNC3_1                         0.045^\*^                              GSE71034
                                                                                                   KCNC4_1                         0.058                                  
                                                                                                   KCND3_1                         0.002^\*\*^                            
                                                                     Cortex primary neuron         KCNA4_1                         0.017^\*^                              
                                                                                                   KCNA4_2                         0.006^\*\*^                            
                                                                                                   KCND2_1                         0.030^\*^                              
                                                                                                   KCND2_2                         0.022^\*^                              
                                                                                                   KCND3_1                         0.020^\*^                              
                                                                     Hippocampus primary neurons   KCND2_1                         0.074                                  
                                                                                                   KCND3_1                         0.072                                  
  Tinnitus                      Mouse (3 months)                     Auditory cortex               KCNA4_1                         0.042^\*^                              65
  Chronic pain                  C57BL/6 X CBA/J mouse (Adult male)   Trigeminal ganglia            KCNC3_1                         0.011^\*^                              GSE69619
                                                                                                   KCND1_1                         0.016^\*^                              
                                                                                                   KCND2_1                         0.063                                  
                                                                                                   KCND2_2                         0.02^\*^                               
  Chronic pain                  C57BL/6 X CBA/J mouse (Adult male)   Trigeminal ganglia            KCND2_3                         0.009^\*\*^                            GSE69619
                                                                                                   KCND2_4                         0.067                                  
                                                                                                   KCND3_1                         0.078                                  
  Ataxia                        Human (Normal vs. Ataxia)            Cerebellum                    KCND2_1                         0.000000007^\*\*^                      GSE61019
                                                                                                   KCND3_1                         0.015^\*^                              
                                C57BL/6 mouse (6 weeks)                                            KCNC4_1                         0.046^\*^                              GSE61908
                                                                                                   KCND1_1                         0.048^\*^                              
                                C57BL/6 mouse (6 weeks)                                            KCND2_1                         0.043^\*^                              
                                                                                                   KCND3_1                         0.042^\*^                              
                                C57BL/6 mouse (24 months)                                          KCNC3_1                         0.061                                  GSE55177
                                                                                                   KCND1_1                         0.032^\*^                              
                                                                                                   KCND2_1                         0.08                                   
                                                                                                   KCND3_1                         0.009^\*\*^                            
                                C57BL/6 mouse (12 months)                                          KCNC3_1                         0.0000007^\*\*^                        
                                                                                                   KCNC3_2                         0.00005^\*\*^                          
                                                                                                   KCNC3_3                         0.011^\*^                              
                                                                                                   KCNC4_1                         0.007^\*\*^                            
                                                                                                   KCNC4_2                         0.007^\*\*^                            
                                                                                                   KCND2_1                         0.079                                  
                                                                                                   KCND3_1                         0.007^\*\*^                            
                                                                                                   KCND3_2                         0.022^\*^                              
                                                                                                   KCND3_3                         0.035^\*^                              
                                C57BL/6 mouse (6 months)                                           KCNA4_1                         0.063                                  
                                                                                                   KCNC3_1                         0.002^\*\*^                            
                                                                                                   KCNC4_1                         0.043^\*^                              
                                                                                                   KCND3_1                         0.068                                  
                                                                                                   KCND3_2                         0.072                                  
                                                                                                   KCND3_3                         0.095                                  
                                                                                                                                                                          

We analyzed human and animal gene expression data from GEO (

http://www.ncbi.nlm.nih.gov/geo

). Data were analyzed by GEO2R (

http://www.ncbi.nlm.nih.gov/geo/geo2r/

). GSE6834 and GSE36980 were analyzed for Alzheimer's disease. GSE20168 and GSE20291 were analyzed for Parkinson's disease. GSE6834 and GSE28674 were analyzed for epilepsy, GSE57034 and GSE71034 were analyzed for fragile X syndrome. GSE69619 was analyzed for Chronic pain. GSE61019, GSE55177, and GSE61908 were analyzed for Ataxia. Tinnitus data was analyzed by Affymetrix. Statistical significance,

∗

p

\< 0.05;

∗∗

p

\< 0.01.

Alzheimer's Disease
===================

Alzheimer disease (AD) is a neurodegenerative disease characterized by progressive deterioration of cognitive function. The early symptoms of AD are found in language, perception, movement, and memory. In the final phase, it causes widespread neuronal death, leading to severe memory loss, emotional disturbance and language dysfunction. Thus, patients' independent living is impossible and relies on caregivers ([@B25]). One potential cause of AD appears to be the abnormal folding of the proteins Tau and/or Amyloid beta (A~β~) ([@B4]). Interestingly, I~A~ channels are downregulated with the plaque of Tau and/or Amyloid beta (A~β~), as reported in a study of cultured hippocampal neurons from an AD animal model ([@B54]). This is further evidenced by other studies that A~β~-induced dendritic hyperexcitability is known to arise from a sustained increase in intracellular Ca^2+^ and dysfunction of I~A~ channels in dendrites on hippocampal CA1 neurons of rodents ([@B25]; [@B82]; [@B47]). The loss of Ca^2+^ homeostasis in dendrites is attributed to abnormally enhanced back-propagation action potentials (bAPs) resulting from dysfunction of I~A~ channels. In other words, the dysfunction of I~A~ channels induced by A~β~ misfolding and aggregation results in excessive dendritic Ca^2+^ influx, leading to the subsequent destruction of synapses and ultimately cell death. In contrast, a study reported that up-regulation of the kv3.4 channel (but not caused by A~β~ deposition) causes alterations of the neuron activity in early AD ([@B4]). In any cases, it is likely that the alteration of I~A~ channels disrupts synaptic function of neurons, being involved in the clinical manifestation of AD.

Epilepsy
========

Epilepsy is characterized by repeated convulsive seizures. Seizures are known to be caused by excessive excitation or suppressed inhibition in neural networks ([@B115], [@B116]; [@B85]). One-third of epilepsy is a generalized seizure often accompanied by loss of consciousness, affecting the entire brain. Two-thirds of epilepsy occurs as focal seizures. Then, it often proceeds into the generalized seizures ([@B5]). Epileptic seizure occurs as the result of environmental factors such as brain injury, stroke, brain tumors and infections, and genetic factors. Also, many of the patients are often accompanied by psychological symptoms such as anxiety and depression ([@B38]; [@B103]; [@B12]). In any case, epileptic seizures are strongly associated with the downregulation of I~A~ channels ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}). In fact, the drugs that downregulate the activity of I~A~ channels have been recognized as pro-convulsants and, therefore, inhibiting the activity and expression of I~A~ channels is the well-established models of epilepsy ([@B13]; [@B98]). Indeed, in adult Wistar rats with spontaneous behavioral seizures, the expression of Kv4.2 is decreased in the hippocampus ([@B71]). Also, in a seizure induction study, pregnant rats were infused with a neurotoxin, MAM (methylazoxymethanol). This neurotoxin reduced DNA synthesis and caused neuronal heterotopia in the hippocampus of the rat fetuses. Postnatally, their hippocampal neurons showed I~A~ channels (encoded by Kv4.2) dysfunctional and exhibited hyperexcitability. As a result, their seizure thresholds were lower than those in normal rats ([@B23]). With status epilepticus induced by kainic acid, the rat model is associated with the activation of extracellular signal-regulated kinase (ERK), an enzyme that causes the structural and functional impairment of dendritic Kv4.2-I~A~ channels ([@B79]). Apart from the expression level change of Kv4.2 in animal seizure model, the hippocampus of Kv4.2 knockout (KO) mice increases the sensitivity to convulsion-inducing stimulation compared to that in wild type mice, indicating the depletion of Kv4.2 is associated with deviant network excitability and increased seizure susceptibility ([@B8]). Consistent with these findings in animals, a study with surgical tissue from patients with hippocampal sclerosis-induced epilepsy showed that the dendritic regions of the hippocampus exhibit the decreased expression of Kv4.2. Similarly, the patient with one temporal lobe epilepsy carried a gene mutation of Kv4.2 channels ([@B93]; [@B6]). Thus, these results suggest that the functional and/or structural reduction of I~A~ channels is associated with abnormal neuronal excitability and epilepsy in the temporal lobe in both animals and humans.

Fragile X Syndrome
==================

Fragile X syndrome (FXS) is the most common heritable mental disability. In general, the person with FXS has a long, narrow face, big ears and flexible fingers, often having autistic behaviors. FXS is associated with the dysfunction of the protein *fragile X mental retardation protein* (FMRP) encoded by a gene FMR1 on the X chromosome, a regulator of protein synthesis in axons and dendrites ([@B32]). FMRP possessing multiple RNA binding domains binds to polyribosome complexes and regulates protein synthesis ([@B7]; [@B94]; [@B18]; [@B43]; [@B73]; [@B101]; [@B30]). Loss of FMRP causes a variety of symptoms such as sensory hypersensitivity and repetitive/excessive behavior which are hallmarks of FXS ([@B83]; [@B19]; [@B14]; [@B122]; [@B125]). Recent findings show that FMRP is associated with the expression and activation of Kv4.2 channels in the mouse hippocampus ([Table 2](#T2){ref-type="table"}). There are two different conclusions on the interactional relation between FMRP and Kv4.2 channels. On one hand, in an *fmr1* KO mouse model, the dendritic protein level of Kv4.2 in the hippocampus was found to be reduced, possibly causing neural hyperexcitability which underlies a plausible mechanism of FXS (and its associated epilepsy) ([@B45]). Also, the finding is supported by a following study with *fmr1* KO mice that Kv4.x-mediated currents are reduced in dendrites, but not soma, of hippocampal CA1 pyramidal neurons, and accordingly the amplitude of back-propagation action potentials (bAPs) is increased in distal dendrites ([@B88]). On the sharp contrary, the local translation of Kv4.2 in CA1 dendrites increases in *fmr1* KO mice, indicating that FMRP is a negative controller of dendritic Kv4.2 ([@B69]). In any cases, dendritic I~A~ channels have been found important in FXS. Further studies are required to explore the dynamic role of dendritic I~A~ channels in FXS.

Parkinson's Disease
===================

Parkinson's disease (PD) is one of the most common neurodegenerative disorders characterized by an impairment of dopaminergic systems. Patients who suffer from PD have problems with voluntary behavior and thinking. Dementia and emotional problems such as depression and anxiety can be gradually developed over time. The cause of PD has several candidates: (1) environmental factors such as exposure to pesticides and a history of head injury and (2) genetic factors related to certain genes including SNCA, LRRK2, GNA, PRKN, PINK1, PARK7, VPS35, EIF4G1, DNAJC13, and CHCHD2 ([@B60]). The pathological hallmark of PD is known to be the loss of dopaminergic neurons in the substantia nigra (SN). Another pathological feature of PD is the formation of protein aggregates called Lewy bodies ([@B31]). Furthermore, PD is also associated with dysfunction of I~A~ channels ([@B68]). For instance, the inhibition of Kv4.3 channels increases the spontaneous activity of nigral dopamine (DA) neurons and disrupts DA release, ultimately inducing the onset of PD ([@B99]). In the research, the enhanced neuronal firing was observed only in DA neurons of the SN, but not in DA neurons of the ventral tegmental area. These animal studies are consistent with findings that I~A~ expression is altered in PD patients, as shown in [Table 3](#T3){ref-type="table"}.

Chronic Pain
============

Chronic pain severely affects most daily activities, disrupting social life with financial burden ([@B17]; [@B16]; [@B50]). Two symptoms dominate the disease: (1) inflammatory pain caused by a tissue reaction to injury or infection and (2) neuropathic pain from nerve injury, which prevails after the primary damage has healed ([@B110]). At the root of chronic pain lies the activity of sensory neurons in the dorsal root ganglion (DRG) and spinal dorsal horn (DH). These neurons are responsible for transmitting nociceptive information from the periphery to the brain. Chronic pain is largely associated with neuronal hyperexcitability of the DRGs and DH neurons. Interestingly, several lines of evidence indicate that these neurons' hyperexcitability is caused by reduced inhibitory currents and/or expression of I~A~ channels in the DRGs and DH neurons (see [Table 2](#T2){ref-type="table"}). For example, in a rat diabetic neuropathy model, the reduction of 4-aminopyridine (4-AP)-sensitive I~A~ currents and the decreased mRNA expression level of I~A~ alpha-subunits; Kv1.4, Kv4.2, and Kv4.3 in the medium and large-diameter DRG neurons leads to the hyperexcitability of the neurons through BDNF activity on TrkB receptor ([@B21]). In addition, by peripheral nerve injury resulting in neuropathic pain, hypoacetylated histone H4 at the location of Kv4.2-NRSE is associated with the decreased mRNA expression of Kv4.3 in mouse DRG neurons, and the reduction of Kv4.3 is implicated in neuronal hyperexcitability ([@B62]; [@B102]). Finally, DRGs in a neuropathic rat model show reduced Kv4.3 protein expression after spinal nerve ligation to DRGs, which drives mechanical hypersensitivity ([@B26]). Apart from DRGs, neurons in the DH of animals with formalin-induced inflammatory chronic pain are Kv4.2-deficient and exhibit increased excitability, resulting in increased sensitivity to tactile and thermal stimuli ([@B55]). Moreover, in a rat model of cystitis with visceral hypersensitivity, the decrease in 4-aminopyridine (4-AP)-sensitive I~A~ current as well as the decreased expression of Kv1.4 channels are observed in DH neurons, leading to neuronal hyperexcitability ([@B49]). In fact, the role of I~A~ channels in chronic pain has so far been studied mostly in the DRGs and DH neurons. It would be of great interest to investigate the role of I~A~ channels along the somatosensory pathway.

Tinnitus
========

Tinnitus is a ringing in the ear that can be perceived even in the absence of external acoustic stimuli. Tinnitus is induced mainly by environmental factors such as traumatic noise, aging and ear infection. Environmental damage to cochlear hair cells alters the activity of the neural networks along the ascending auditory pathway, increasing the ratio of excitation to inhibition in central auditory neurons. Our group previously reported that auditory neurons in animals with noise-induced tinnitus exhibit intrinsic hyperexcitability. Also, in our preliminary data, noise-induced tinnitus is probably associated with the downregulation of Kv1.4 channels in rat auditory neurons ([@B120]; [@B100]). Thus, we believe this hyperexcitability to be due to the abnormal expression and/or function of I~A~ channels ([Table 2](#T2){ref-type="table"}).

Ataxia
======

Ataxia is a neurodegenerative disorder caused by neural atrophy along the cerebellum-spine axis. Patients suffer from movement discoordination such as progressive ataxic gait and limb movements as well as difficulties with speech and eye movements ([@B36]). Ataxia has three types depending on the parts of the dysfunction: (1) cerebellar ataxia due to dysfunction of the cerebellum; (2) sensory ataxia due to dysfunction of the sensory system including dorsal columns of the spinal cord, thalamus and parietal lobes; (3) vestibular ataxia due to dysfunction of the vestibular system. The main causes of ataxia are the focal lesion of corresponding CNS region, the exogenous substance like ethanol and vitamin b12 deficiency. Besides, genetic factors affect the degeneration of the cerebellum and/or the spine; 22 genes related to spinocerebellar ataxia (SCA) have been identified so far ([@B37]; [@B90]). The mRNA of Kv4.3 channels is highly expressed in the cerebellum of humans ([Figure 1](#F1){ref-type="fig"}). Indeed, in animals and human patients with ataxia ([Table 3](#T3){ref-type="table"}), Kv4.3 channel mRNA expression is altered. For example, SCA type 19 and 22 are caused by mutation of Kv4.3 gene ([@B34], [@B35]; [@B70]; [Table 2](#T2){ref-type="table"}). In addition to Kv4.2 channels, Kv3.3 is the causative gene of SCA type 13, an autosomal dominant neurological disorder ([@B126]). There are lines of evidence that SCA type 13 is caused by point mutations in the coding region of the Kv3.3 gene on chromosome 19q13 ([@B51]; [@B108], [@B109]; [@B126]). Moreover, the expression and function of Kv3.3 channels are altered in CHO cells transfected with mutated SCA13 as well as mRNA expression of Kv3.3 in animal with cerebellar ataxia ([@B51]; [@B108], [@B109]; [@B126]); [Table 3](#T3){ref-type="table"}). Taken all together, the alteration of I~A~ channels is deeply involved in several types of ataxia.

Cellular Mechanisms and Therapeutic Targets of I~A~
===================================================

I~A~ channels and Ca^2+^-permeable channels including NMDA receptors (NMDARs) and voltage-gated calcium channels (VGCCs) are abundant in dendrites, and their interaction determines the level of dendritic excitability and synaptic plasticity ([@B40]; [@B20]; [@B77]; [@B64]; [@B59]; [@B78]; [@B107]; [@B121]). Ca^2+^ channels are kinetically slow to activate and inactivate ([Figure 2A](#F2){ref-type="fig"}; [@B121]). Ca^2+^ dendritic spikes are regenerative and, thus, difficult to regulate once initiated. To efficiently suppress Ca^2+^-mediated hyperexcitability, an active filter is required just before it occurs. Rapid action of I~A~ channels may play such a role as the active filter. For instance, NMDA spikes are mostly induced in distal dendrites of cortical neurons where most synaptic events occur ([@B67]; [@B118], [@B117], [@B119]). In turn, VGCCs magnify the NMDA-mediated dendritic spikes in apical dendrites, propagating the spikes to the axo-somatic sodium spikes zone for AP generation. Here, I~A~ channels could suppress the anterograde propagation of local Na^+^- and Ca^2+^-mediated signals from dendrites as well as the backward spread of APs into dendrites ([@B77]; [@B78]). When I~A~ channels are not active, the conductance of Ca^2+^-permeable channels can easily cause the membrane to slip toward depolarization, leading to synaptic enhancement in the axon terminals. In fact, internalization-induced reduction of I~A~ channels enhances synaptic plasticity while increased I~A~ channels do not display synaptic plasticity, suggesting a synaptic role of Ca^2+^-permeable channels heavily relying on the activity of I~A~ channels ([@B64]; [@B59]). The activity of Ca^2+^-permeable channels which are inflated by inactive I~A~ channels can often cause excessive neuronal excitability, resulting in an imbalance of excitation and inhibition in the whole network. We view this mechanism as a common cause for brain diseases such as Alzheimer's disease, epilepsy, FXS, Parkinson's disease, chronic pain, tinnitus and ataxia ([Figure 2B](#F2){ref-type="fig"}).

![The contribution of I~A~ channels on neuron excitability and brain disease. **(Ai)** A schematic of two photoactivated locations (distal and apical trunk) of a hippocampal neuron. **(Aii)** Examplar gluEPSPs (or glutamate-evoked EPSPs) in response to photoactivation in the distal and apical trunk. Note that there is a sudden increase in the response, being referred to as a NMDA-dependent dendritic spike and Ca^2+^-dependent dendritic spike in the distal and apical trunk, respectively. **(Aiii)** The blockage of 4-AP (3 mM) sensitive-I~A~ channels potentiates the responses of NMDARs but not AMPARs. The left traces illustrate NMDAR (and VGCC)-mediated EPSPs, respectively, in a thin oblique dendrite or in an apical dendrite over an input strength; weak (averaged *6.3 μJ*) and strong (averaged *11.2 μJ*) energy. The right traces illustrate AMPAR-mediated EPSPs in a thin oblique dendrite over an input strength; weak (averaged *2.4 μJ*) and strong (averaged *4.3 μJ*) energy. **(B)** A putative model regarding the contribution of I~A~ channels on neuron excitability and brain disease. It shows a molecular mechanism that dendritic impairment of I~A~ channels can augment AP generation. The data was reused with permission from [@B121].](fncel-13-00265-g002){#F2}

Most drugs that are currently used to treat these diseases directly modulate ion channels and receptors that affect intrinsic and synaptic properties. However, as most of these ion channel-related drugs act across the whole brain, they produce a wide range of non-specific side effects, leading to the discontinuation of many potential treatments in the past. For instance, antagonists of NMDA receptors and voltage-sensitive sodium channels could in principle be used to suppress hyperexcitability. However, they also disrupt the physiological function of unintended brain areas. Furthermore, the drugs that activate GABA receptors also suppress other brain areas, often resulting in sedating and over-suppression effects that significantly reduce the quality of life. One way to circumvent these limitations of classical excitatory or inhibitory drugs would be to develop chemical compounds that "indirectly" modulate Na^+^ channels, NMDA or GABA receptors. A recent study reports that the application of 4-AP restores low- and high-threshold dendritic spikes in the distal and apical dendrites, respectively, which can be driven by Ca^2+^-permeable channels (NMDARs and/or Ni^2+^-sensitive voltage-gated Ca^2+^ channels) in rat hippocampal CA1 neurons ([@B121]). A similar study demonstrates that glutamate-mediated dendritic spikes are enhanced by 4-AP treatment and normalized by D-AP5 (an NMDA receptor antagonist) in mouse L3 pyramidal neuron ([@B15]). Thus, Ca^2+^-permeable channels and I~A~ channels play a counterbalancing role in regulating neuronal excitability ([Figure 2](#F2){ref-type="fig"}). In this respect, I~A~ channels as an indirect modulator can be predominantly activated in a hyperexcitable condition caused by excessive activity of Ca^2+^-permeable channels, yet having minimal impact on the resting condition of neurons. Furthermore, given homeostatic regulation of neural networks, the lack of sensory or modulatory inputs likely causes the increment of excitation and/or decrement of inhibition in the affected neurons. These changes seem to be required for maintaining network excitability for neuron survival. In the hyperexcitable condition of the affected neurons often causing brain disorders, for example, an agonist of I~A~ channels can function to modulate neuronal excitability by counteracting against Ca^2+^-permeable channels/receptors. Thus, I~A~ channels as a therapeutic target may open an avenue for more sustainable treatments of brain disease with minimal interference in normal physiological function, leading to long-term clinical benefits. However, it is notable that there are limitations incurred when attempting to link the animal disease model to human neuropathology in the context of the expression and function of I~A~ channels. It is currently unclear whether the suggested therapeutic mechanism of I~A~ channels with animal disease models can apply to human diseases having a different neural network. Further research is required to delineate the precise contributions of I~A~ channels to brain diseases in human.
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